Milestone Scientific (NYSE American: MLSS) disclosed that directors filed conversion notices covering $116,495.47, $58,247.73 and $291,238.66 of outstanding convertible bridge notes, which will automatically convert once the stock’s fair value reaches $0.50 per share. The potential conversion adds dilution risk but could bring additional equity capital as the stock trades near its 52‑week high.

Key Highlights

  • Directors submitted notices for $116,495.47, $58,247.73 and $291,238.66 of convertible bridge notes.
  • Notices automatically convert when the stock’s fair value reaches $0.50 per share.

Milestone Scientific Inc. (NYSE American: MLSS) announced that three of its directors have submitted conversion notices covering substantial portions of the company’s convertible bridge notes. The notices represent principal amounts of $116,495.47, $58,247.73 and $291,238.66 respectively, and will become effective once the common stock’s fair value meets a $0.50 per‑share threshold.

Director Conversion Notices Filed

The conversion notices were filed by Benedetta Casamento, Dr. Their individual notice amounts stand at $116,495.47 for Ms. Casamento, $58,247.73 for Dr.

Demesmin, and $291,238.66 for Mr. Goldman. These figures represent the portions of the original bridge notes that remain outstanding after an earlier partial conversion tied to a private placement on Apr 20 2026.

By invoking the conversion mechanism, the directors signal readiness to transform debt into equity, a move that could reshape the company’s capital structure if the fair‑value trigger is met.

Mechanics of the Convertible Bridge Notes

The bridge notes were originally issued with an aggregate principal of $800,000, a figure disclosed in the company’s earlier financing disclosures. Following the Apr 20 2026 private placement, a portion of the notes converted into shares, leaving the three directors with the balances listed above. The conversion terms stipulate that the notes automatically convert when the common stock’s fair value equals or exceeds $0.50 per share, provided the holder is eligible to trade under the insider‑trading policy.

No shares have been issued under these notices to date, meaning the potential equity dilution remains prospective until the price condition materializes. The stock’s 17.5% gain over the last month underscores investor optimism, likely fueled by the recent financing activity and the prospect of additional equity capital without further cash outlays. However, the $0.50 fair‑value trigger sits above the current market price, suggesting that conversion will only occur if the share price appreciates substantially.

This dynamic creates a balance between anticipated dilution and the benefit of a stronger balance sheet should the conversion take place.

Forward Catalyst: Fair‑Value Test

The next key event is the automatic conversion condition tied to a fair value of $0.50 per share. Once the market price reaches or exceeds this level, the conversion notices will activate without further shareholder action. Analysts will watch the stock’s trajectory closely, especially as it approaches the $0.50 threshold, a price point that lies near the midpoint of its 52‑week range.

The timing of this trigger will dictate the scale of equity issuance and the resultant impact on ownership percentages. Investors should monitor price movements and any related disclosures for clues on when the conversion may occur.

Analysis based on the Form 8-K filed 29 July 2026.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.